



Celldex Therapeutics, Inc.  
 Investor Relations Department  
 119 Fourth Avenue  
 Needham, MA 02494-2725  
 United States

Visit IR website [↗](#)  
 Sign-up for email alerts [↗](#)

**NASDAQ: CLDX** <sup>1</sup>

Last Trade:	2.92
Trade Time:	4:00 PM ET Oct 20, 2017
Change:	-0.05 <span style="color:red">↓</span> (1.684%)
Day Range	2.88 - 3.00
52-Week Range	2.20 - 5.02
Volume	715,532
Market Cap. (\$M)	374.753
Shares Out (M)	128.340

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

**Company Profile**

Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- Oct 3, 2017  
[Celldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory Affairs](#)
- Sep 22, 2017  
[Celldex Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference](#)
- Sep 12, 2017  
[Celldex Announces Departure of Chief Medical Officer](#)
- Aug 23, 2017  
[Celldex Announces Completion of Enrollment in Phase 2b Study of Glembatumumab Vedotin in Triple Negative Breast Cancer](#)
- Aug 8, 2017  
[Celldex Reports Second Quarter 2017 Results](#)

**Events** [\[ View all \]](#)

There are no events to display at this time. Please check back later.

**Financials** [\[ View all \]](#)

[Second Quarter Financial Results](#)

- Mar 14, 2017  
[Annual Report \(10-K\)](#)
- Apr 28, 2017  
[Definitive Proxy Statement](#)
- Aug 8, 2017  
[Quarterly Report \(10-Q\)](#)
- May 9, 2017  
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2016  
[Quarterly Report \(10-Q\)](#)